Tag: IBD
New IBD Treatments Target True Healing, Not Just Symptoms
IBD treatment is evolving beyond just managing symptoms to achieving true healing at the cellular level. This shift toward “deep remission” and mucosal healing offers new hope for people with Crohn’s disease and ulcerative colitis, potentially changing the long-term trajectory of these conditions.
New FDA Approval Brings Fresh Hope to IBD Patients
AbbVie’s FDA approval for Rinvoq in IBD treatment offers new hope for patients with moderate to severe Crohn’s and ulcerative colitis. This once-daily medication could provide relief for those who haven’t responded well to traditional therapies.
Finding Your Path Through Crohn’s: From Confusion to Clarity
A comprehensive look at Crohn’s disease symptoms, diagnosis, and treatment offers hope and practical guidance for navigating this complex condition. Understanding your IBD journey is the first step toward regaining control and living well.
New Hope: A Clear Treatment Path for Kids with IBD
A new evidence-based treatment algorithm for pediatric IBD offers families a clearer roadmap through childhood IBD care. This specialized approach recognizes that kids aren’t just small adults and deserve treatment plans designed for their unique developmental needs.
Microbiome Research Offers New Hope for Kids with IBD
New research reveals how gut bacteria patterns in children with IBD might predict disease progression and guide future treatments. This groundbreaking study offers hope for more personalized pediatric IBD care based on microbiome analysis.
New Treatment Option Approved for Crohn’s After TNF Failure
The FDA has approved upadacitinib (Rinvoq) for adults with moderate to severe Crohn’s disease who haven’t responded well to TNF blockers. This gives patients and doctors a new treatment option with a different mechanism of action, backed by strong clinical trial data showing both symptom improvement and intestinal healing.
A Champion for IBD Patients: Dr. Cross Receives Prestigious Award
Dr. Raymond Cross has been named recipient of the 2026 Medical Champion Award by the Crohn’s & Colitis Foundation. His recognition highlights the importance of comprehensive, compassionate IBD care and offers hope for continued advances in treatment and patient advocacy.
New IBD Treatment Hope: EVerZom Raises $10M for Innovation
EVerZom secures $10 million to develop revolutionary exosome-based therapies for inflammatory diseases like Crohn’s and UC. Here’s what this breakthrough could mean for the IBD community and why it represents genuine hope for better treatments ahead.
New FDA-Approved Treatment Offers Hope for Tough Crohn’s Cases
The FDA’s approval of Rinvoq for Crohn’s disease offers new hope specifically for patients who haven’t responded to traditional anti-TNF therapies. This oral JAK inhibitor represents a different approach to controlling inflammation and could be a game-changer for those who have run out of treatment options.
New FDA-Approved IBD Treatment Offers Hope for Difficult Cases
The FDA has approved Rinvoq, a new once-daily oral treatment for moderate to severe Crohn’s disease and ulcerative colitis. This JAK inhibitor offers hope for patients who haven’t found success with traditional therapies, with some seeing improvement in as little as eight weeks.
